Trials / Sponsors / MedDay Pharmaceuticals SA

MedDay Pharmaceuticals SA

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Completed	Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjec Healthy Volunteers	Phase 1	2019-12-10
Unknown	TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects Healthy Volunteers	Phase 1	2019-11-11
Terminated	HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healt Healthy Volunteers, Hepatic Impairment of Moderate Child Pugh Category	Phase 1	2019-10-11
Terminated	RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Healthy Volunteers, Impaired Renal Function	Phase 1	2019-10-09
Completed	SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease	Phase 2	2016-12-05
Terminated	Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Multiple Sclerosis	Phase 3	2016-12-01
Completed	Effect of MD1003 in Amyotrophic Lateral Sclerosis ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease	Phase 2	2016-06-29
Completed	MD1003-AMN MD1003 in Adrenomyeloneuropathy Adrenomyeloneuropathy, Adrenoleukodystrophy, AMN	Phase 2 / Phase 3	2014-10-01
Unknown	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Multiple Sclerosis	Phase 3	2013-10-01
Unknown	Effect of MD1003 in Spinal Progressive Multiple Sclerosis Multiple Sclerosis	Phase 3	2013-10-01